These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 15660959)

  • 41. Modulation of GPCR conformations by ligands, G-proteins, and arrestins.
    Prossnitz ER; Sklar LA
    Ernst Schering Found Symp Proc; 2006; (2):211-28. PubMed ID: 17703584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GPCR-GIP networks: a first step in the discovery of new therapeutic drugs?
    Bockaert J; Dumuis A; Fagni L; Marin P
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):649-57. PubMed ID: 15503867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling small molecule-compound binding to G-protein-coupled receptors.
    Vaidehi N; Pease JE; Horuk R
    Methods Enzymol; 2009; 460():263-88. PubMed ID: 19446730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New concepts in drug discovery: collateral efficacy and permissive antagonism.
    Kenakin T
    Nat Rev Drug Discov; 2005 Nov; 4(11):919-27. PubMed ID: 16264435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Class-B GPCR activation: is ligand helix-capping the key?
    Neumann JM; Couvineau A; Murail S; Lacapère JJ; Jamin N; Laburthe M
    Trends Biochem Sci; 2008 Jul; 33(7):314-9. PubMed ID: 18555686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation.
    Rubenstein LA; Zauhar RJ; Lanzara RG
    J Mol Graph Model; 2006 Dec; 25(4):396-409. PubMed ID: 16574446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms.
    Beinborn M; Ren Y; Bläker M; Chen C; Kopin AS
    Mol Pharmacol; 2004 Mar; 65(3):753-60. PubMed ID: 14978254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Asymmetry of GPCR oligomers supports their functional relevance.
    Maurice P; Kamal M; Jockers R
    Trends Pharmacol Sci; 2011 Sep; 32(9):514-20. PubMed ID: 21715028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extracellular loops and ligand binding to a subfamily of Family A G-protein-coupled receptors.
    Wheatley M; Simms J; Hawtin SR; Wesley VJ; Wootten D; Conner M; Lawson Z; Conner AC; Baker A; Cashmore Y; Kendrick R; Parslow RA
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):717-20. PubMed ID: 17635132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. G protein-coupled receptor pharmacogenetics.
    Thompson MD; Siminovitch KA; Cole DE
    Methods Mol Biol; 2008; 448():139-85. PubMed ID: 18370234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recognition of GPCRs by peptide ligands and membrane compartments theory: structural studies of endogenous peptide hormones in membrane environment.
    Sankararamakrishnan R
    Biosci Rep; 2006 Apr; 26(2):131-58. PubMed ID: 16773462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel pharmacological applications of G-protein-coupled receptor-G protein fusions.
    Milligan G; Parenty G; Stoddart LA; Lane JR
    Curr Opin Pharmacol; 2007 Oct; 7(5):521-6. PubMed ID: 17689289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of 16 human G protein-coupled receptors expressed in baculovirus-infected insect cells.
    Akermoun M; Koglin M; Zvalova-Iooss D; Folschweiller N; Dowell SJ; Gearing KL
    Protein Expr Purif; 2005 Nov; 44(1):65-74. PubMed ID: 15951199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. G-protein-coupled receptor pharmacology: examining the edges between theory and proof.
    Gilchrist A; Blackmer T
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):446-51. PubMed ID: 17659486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors.
    O'Dowd BF; Alijaniaram M; Ji X; Nguyen T; Eglen RM; George SR
    J Biomol Screen; 2007 Mar; 12(2):175-85. PubMed ID: 17289935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of constitutively active mutants of G protein-coupled receptors.
    Navenot JM; Wang ZX; Peiper SC
    Methods Mol Biol; 2006; 332():129-39. PubMed ID: 16878689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms.
    Lewandowicz AM; Vepsäläinen J; Laitinen JT
    Br J Pharmacol; 2006 Feb; 147(4):422-9. PubMed ID: 16402041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. G protein activation by G protein coupled receptors: ternary complex formation or catalyzed reaction?
    Roberts DJ; Waelbroeck M
    Biochem Pharmacol; 2004 Sep; 68(5):799-806. PubMed ID: 15294442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.